Radiofrequency Ablation Guided by Contrast-Enhanced Sonography versus B-Mode Sonography for Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization
Purpose: Contrast-enhanced sonography increases negative enhancement in the Kupffer phase after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We compared contrast-enhanced sonography with B-mode sonography for guidance of radiofrequency ablation (RFA) of HCC aft...
Gespeichert in:
| Veröffentlicht in: | Digestive diseases (Basel) 2016-01, Vol.34 (6), p.692-695 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 695 |
|---|---|
| container_issue | 6 |
| container_start_page | 692 |
| container_title | Digestive diseases (Basel) |
| container_volume | 34 |
| creator | Kawasaki, Toshihiko Hata, Kan-yun Kinoshita, Daisuke Takayama, Masaki Okuda, Hideyuki Mizuno, Shigeto Kudo, Masatoshi |
| description | Purpose: Contrast-enhanced sonography increases negative enhancement in the Kupffer phase after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We compared contrast-enhanced sonography with B-mode sonography for guidance of radiofrequency ablation (RFA) of HCC after TACE. Methods: After TACE was performed, 18 nodules in 12 patients were treated by B-mode sonography guided RFA, while 22 nodules in 18 patients were treated by contrast-enhanced sonography-guided RFA. Results: The success rate of initial RFA was 83.3% (15/18 nodules) in the B-mode sonography group. On the other hand, the success rate was 100% (22/22 nodules) in the contrast-enhanced sonography group and the difference was significant (p = 0.046). Conclusion: These findings suggest that RFA guided by Kupffer phase contrast-enhanced sonography after TACE is a promising therapeutic option for curing HCC. |
| doi_str_mv | 10.1159/000448858 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_448858</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1835450390</sourcerecordid><originalsourceid>FETCH-LOGICAL-c334t-2e3be4a04f395f13ebd361f24c9ebb6d610c1d11d661d1097cd54efaec9ffb513</originalsourceid><addsrcrecordid>eNptkU9v1DAQxQ0F0W3pgTtClnqBQ8CO7SQ-LulfqQgJyjma2ONuIIlTO0Favg5ftNnudsWBi0ee95un0TxC3nD2kXOlPzHGpCwKVTwjR0LwgimtGH9OFlymPNFFrg7Iic6LnSZ19oIsWKryJM2VOCRHMf5kbHbKs1fkMM1zxVKhF-TvN7CNdwHvJ-zNmi7rFsbG9_RyaixaWq9p6fsxQByT834FvZmb333v7wIMqzX9jSFOkX5OvniL_wrOB3qFA4zeYNtOLQRaQjBN7zug4EYM9DZAHw2MK9z8lmF-G2hpucLOY1f7tvnzuMtr8tJBG_FkV4_Jj4vz2_Iqufl6eV0ubxIjhByTFEWNEph0QivHBdZWZNyl0mis68xmnBluObdZNhemc2OVRAdotHO14uKYvN_6DsHP54hj1TVxsz306KdY8UIoqZjQbEY_bFETfIwBXTWEpoOwrjirNoFV-8Bm9t3Odqo7tHvyKYQZeLsFfkG4w7AH9vOn_5XPzq63RDVYJx4AIEulIw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835450390</pqid></control><display><type>article</type><title>Radiofrequency Ablation Guided by Contrast-Enhanced Sonography versus B-Mode Sonography for Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization</title><source>MEDLINE</source><source>Karger Journals</source><source>Alma/SFX Local Collection</source><creator>Kawasaki, Toshihiko ; Hata, Kan-yun ; Kinoshita, Daisuke ; Takayama, Masaki ; Okuda, Hideyuki ; Mizuno, Shigeto ; Kudo, Masatoshi</creator><creatorcontrib>Kawasaki, Toshihiko ; Hata, Kan-yun ; Kinoshita, Daisuke ; Takayama, Masaki ; Okuda, Hideyuki ; Mizuno, Shigeto ; Kudo, Masatoshi</creatorcontrib><description>Purpose: Contrast-enhanced sonography increases negative enhancement in the Kupffer phase after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We compared contrast-enhanced sonography with B-mode sonography for guidance of radiofrequency ablation (RFA) of HCC after TACE. Methods: After TACE was performed, 18 nodules in 12 patients were treated by B-mode sonography guided RFA, while 22 nodules in 18 patients were treated by contrast-enhanced sonography-guided RFA. Results: The success rate of initial RFA was 83.3% (15/18 nodules) in the B-mode sonography group. On the other hand, the success rate was 100% (22/22 nodules) in the contrast-enhanced sonography group and the difference was significant (p = 0.046). Conclusion: These findings suggest that RFA guided by Kupffer phase contrast-enhanced sonography after TACE is a promising therapeutic option for curing HCC.</description><identifier>ISSN: 0257-2753</identifier><identifier>ISBN: 9783318059496</identifier><identifier>ISBN: 3318059498</identifier><identifier>EISSN: 1421-9875</identifier><identifier>EISBN: 3318059501</identifier><identifier>EISBN: 9783318059502</identifier><identifier>DOI: 10.1159/000448858</identifier><identifier>PMID: 27750239</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Aged ; Aged, 80 and over ; Antibiotics, Antineoplastic - administration & dosage ; Carcinoma, Hepatocellular - therapy ; Catheter Ablation - methods ; Chemoembolization, Therapeutic - methods ; Contrast Media ; Epirubicin - administration & dosage ; Female ; Follow-Up Studies ; Humans ; Image Enhancement - methods ; Liver Neoplasms - therapy ; Male ; Middle Aged ; Original Article ; Remission Induction ; Treatment Outcome ; Ultrasonography, Interventional - methods</subject><ispartof>Digestive diseases (Basel), 2016-01, Vol.34 (6), p.692-695</ispartof><rights>2016 S. Karger AG, Basel</rights><rights>2016 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c334t-2e3be4a04f395f13ebd361f24c9ebb6d610c1d11d661d1097cd54efaec9ffb513</citedby><cites>FETCH-LOGICAL-c334t-2e3be4a04f395f13ebd361f24c9ebb6d610c1d11d661d1097cd54efaec9ffb513</cites><orcidid>0000-0002-4102-3474</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27750239$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kawasaki, Toshihiko</creatorcontrib><creatorcontrib>Hata, Kan-yun</creatorcontrib><creatorcontrib>Kinoshita, Daisuke</creatorcontrib><creatorcontrib>Takayama, Masaki</creatorcontrib><creatorcontrib>Okuda, Hideyuki</creatorcontrib><creatorcontrib>Mizuno, Shigeto</creatorcontrib><creatorcontrib>Kudo, Masatoshi</creatorcontrib><title>Radiofrequency Ablation Guided by Contrast-Enhanced Sonography versus B-Mode Sonography for Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization</title><title>Digestive diseases (Basel)</title><addtitle>Dig Dis</addtitle><description>Purpose: Contrast-enhanced sonography increases negative enhancement in the Kupffer phase after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We compared contrast-enhanced sonography with B-mode sonography for guidance of radiofrequency ablation (RFA) of HCC after TACE. Methods: After TACE was performed, 18 nodules in 12 patients were treated by B-mode sonography guided RFA, while 22 nodules in 18 patients were treated by contrast-enhanced sonography-guided RFA. Results: The success rate of initial RFA was 83.3% (15/18 nodules) in the B-mode sonography group. On the other hand, the success rate was 100% (22/22 nodules) in the contrast-enhanced sonography group and the difference was significant (p = 0.046). Conclusion: These findings suggest that RFA guided by Kupffer phase contrast-enhanced sonography after TACE is a promising therapeutic option for curing HCC.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibiotics, Antineoplastic - administration & dosage</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Catheter Ablation - methods</subject><subject>Chemoembolization, Therapeutic - methods</subject><subject>Contrast Media</subject><subject>Epirubicin - administration & dosage</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Image Enhancement - methods</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Remission Induction</subject><subject>Treatment Outcome</subject><subject>Ultrasonography, Interventional - methods</subject><issn>0257-2753</issn><issn>1421-9875</issn><isbn>9783318059496</isbn><isbn>3318059498</isbn><isbn>3318059501</isbn><isbn>9783318059502</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkU9v1DAQxQ0F0W3pgTtClnqBQ8CO7SQ-LulfqQgJyjma2ONuIIlTO0Favg5ftNnudsWBi0ee95un0TxC3nD2kXOlPzHGpCwKVTwjR0LwgimtGH9OFlymPNFFrg7Iic6LnSZ19oIsWKryJM2VOCRHMf5kbHbKs1fkMM1zxVKhF-TvN7CNdwHvJ-zNmi7rFsbG9_RyaixaWq9p6fsxQByT834FvZmb333v7wIMqzX9jSFOkX5OvniL_wrOB3qFA4zeYNtOLQRaQjBN7zug4EYM9DZAHw2MK9z8lmF-G2hpucLOY1f7tvnzuMtr8tJBG_FkV4_Jj4vz2_Iqufl6eV0ubxIjhByTFEWNEph0QivHBdZWZNyl0mis68xmnBluObdZNhemc2OVRAdotHO14uKYvN_6DsHP54hj1TVxsz306KdY8UIoqZjQbEY_bFETfIwBXTWEpoOwrjirNoFV-8Bm9t3Odqo7tHvyKYQZeLsFfkG4w7AH9vOn_5XPzq63RDVYJx4AIEulIw</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Kawasaki, Toshihiko</creator><creator>Hata, Kan-yun</creator><creator>Kinoshita, Daisuke</creator><creator>Takayama, Masaki</creator><creator>Okuda, Hideyuki</creator><creator>Mizuno, Shigeto</creator><creator>Kudo, Masatoshi</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4102-3474</orcidid></search><sort><creationdate>20160101</creationdate><title>Radiofrequency Ablation Guided by Contrast-Enhanced Sonography versus B-Mode Sonography for Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization</title><author>Kawasaki, Toshihiko ; Hata, Kan-yun ; Kinoshita, Daisuke ; Takayama, Masaki ; Okuda, Hideyuki ; Mizuno, Shigeto ; Kudo, Masatoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c334t-2e3be4a04f395f13ebd361f24c9ebb6d610c1d11d661d1097cd54efaec9ffb513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibiotics, Antineoplastic - administration & dosage</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Catheter Ablation - methods</topic><topic>Chemoembolization, Therapeutic - methods</topic><topic>Contrast Media</topic><topic>Epirubicin - administration & dosage</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Image Enhancement - methods</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Remission Induction</topic><topic>Treatment Outcome</topic><topic>Ultrasonography, Interventional - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kawasaki, Toshihiko</creatorcontrib><creatorcontrib>Hata, Kan-yun</creatorcontrib><creatorcontrib>Kinoshita, Daisuke</creatorcontrib><creatorcontrib>Takayama, Masaki</creatorcontrib><creatorcontrib>Okuda, Hideyuki</creatorcontrib><creatorcontrib>Mizuno, Shigeto</creatorcontrib><creatorcontrib>Kudo, Masatoshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kawasaki, Toshihiko</au><au>Hata, Kan-yun</au><au>Kinoshita, Daisuke</au><au>Takayama, Masaki</au><au>Okuda, Hideyuki</au><au>Mizuno, Shigeto</au><au>Kudo, Masatoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiofrequency Ablation Guided by Contrast-Enhanced Sonography versus B-Mode Sonography for Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization</atitle><jtitle>Digestive diseases (Basel)</jtitle><addtitle>Dig Dis</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>34</volume><issue>6</issue><spage>692</spage><epage>695</epage><pages>692-695</pages><issn>0257-2753</issn><eissn>1421-9875</eissn><isbn>9783318059496</isbn><isbn>3318059498</isbn><eisbn>3318059501</eisbn><eisbn>9783318059502</eisbn><abstract>Purpose: Contrast-enhanced sonography increases negative enhancement in the Kupffer phase after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We compared contrast-enhanced sonography with B-mode sonography for guidance of radiofrequency ablation (RFA) of HCC after TACE. Methods: After TACE was performed, 18 nodules in 12 patients were treated by B-mode sonography guided RFA, while 22 nodules in 18 patients were treated by contrast-enhanced sonography-guided RFA. Results: The success rate of initial RFA was 83.3% (15/18 nodules) in the B-mode sonography group. On the other hand, the success rate was 100% (22/22 nodules) in the contrast-enhanced sonography group and the difference was significant (p = 0.046). Conclusion: These findings suggest that RFA guided by Kupffer phase contrast-enhanced sonography after TACE is a promising therapeutic option for curing HCC.</abstract><cop>Basel, Switzerland</cop><pmid>27750239</pmid><doi>10.1159/000448858</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-4102-3474</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0257-2753 |
| ispartof | Digestive diseases (Basel), 2016-01, Vol.34 (6), p.692-695 |
| issn | 0257-2753 1421-9875 |
| language | eng |
| recordid | cdi_karger_primary_448858 |
| source | MEDLINE; Karger Journals; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Antibiotics, Antineoplastic - administration & dosage Carcinoma, Hepatocellular - therapy Catheter Ablation - methods Chemoembolization, Therapeutic - methods Contrast Media Epirubicin - administration & dosage Female Follow-Up Studies Humans Image Enhancement - methods Liver Neoplasms - therapy Male Middle Aged Original Article Remission Induction Treatment Outcome Ultrasonography, Interventional - methods |
| title | Radiofrequency Ablation Guided by Contrast-Enhanced Sonography versus B-Mode Sonography for Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T07%3A18%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiofrequency%20Ablation%20Guided%20by%20Contrast-Enhanced%20Sonography%20versus%20B-Mode%20Sonography%20for%20Hepatocellular%20Carcinoma%20after%20Transcatheter%20Arterial%20Chemoembolization&rft.jtitle=Digestive%20diseases%20(Basel)&rft.au=Kawasaki,%20Toshihiko&rft.date=2016-01-01&rft.volume=34&rft.issue=6&rft.spage=692&rft.epage=695&rft.pages=692-695&rft.issn=0257-2753&rft.eissn=1421-9875&rft.isbn=9783318059496&rft.isbn_list=3318059498&rft_id=info:doi/10.1159/000448858&rft_dat=%3Cproquest_karge%3E1835450390%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&rft.eisbn=3318059501&rft.eisbn_list=9783318059502&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835450390&rft_id=info:pmid/27750239&rfr_iscdi=true |